Daxor Highlights Pilot Study Showing Fluid Assessment Errors In Sepsis, COVID-19 Patients

Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study

Oak Ridge, TN, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today highlighted the significant findings of a new pilot study published in the Journal of Critical Care. Co-authored by leading intensive care expert Jan Bakker, M.D., Ph.D., this pivotal research reveals frequent inaccuracies in how doctors clinically assess fluid levels in critically ill patients with sepsis and COVID-19.

The research, titled, "Endothelial dysfunction in critically ill patients with sepsis and COVID-19 using the albumin transudation rate: A pilot study," found that patients were often misclassified during clinical assessment, with many mistakenly believed to be "hypervolemic" (fluid overloaded) when objective measurements showed them to be "hypovolemic" (fluid deficient), and vice-versa. This critical discrepancy can lead to insufficient fluid administration or dangerous fluid overload, highlighting a significant challenge in critical care.